TOSCCAA-TXA: Treatment Of Stroke reCurrence in Cerebral Amyloid Angiopathy with TraneXamic Acid
Lead PI: Professor Geoffrey Cloud
Status: Recruitment due to start mid-2025
Participating Sites: Alfred Heath (VIC) and Royal Melbourne Hospital (VIC)
No. of Patients Required: 60
TOSCCAA-TXA is a phase 2 double blinded randomised controlled clinical trial assessing the safety and feasibility of Tranexamic Acid for prevention of recurrent intracranial haemorrhage in adults with probable Cerebral Amyloid Angiopathy (CAA) and symptomatic intracranial bleeding within the last 6 months. Treatment will be for 6 months with 12 months of follow up. Primary outcomes will include feasibility measures (participation and adherence rates) and safety (monitoring for serious adverse thrombotic events like DVT/PE, MI, strokes, or death). Secondary outcomes will track the recurrence of CAA related brain haemorrhages, progression of white matter changes, changes in cognitive function, and brain volume loss, as well as the development of new areas of ‘silent’ or asymptomatic stroke on MRI
ACTRN12624001477516
(https://www.anzctr.org.au/ACTRN12624001477516.aspx)
Contact: Pamela Galindo, Trial Manager: tosccaatxa@alfred.org.au
